Both organizations plan to contribute their respective areas of expertise to work on two research projects to improve patient treatment options and outcomes.
Researchers screened cancer cell lines to detect mutations and drug combinations that might sensitize tumors to drugs that impair anti-apoptosis proteins.
A proteomic analysis of pancreatic ductal adenocarcinoma tumor and stromal samples led to a stromal protein that appears to coincide with tumor aggressiveness.
Researchers saw abbreviated overall survival times in estrogen receptor-positive metastatic breast cancer patients with ESR1 mutations in their cell-free DNA.
Researchers used genomic approaches to search for disease clues in purified cells from ileum or colon biopsies of pediatric inflammatory bowel disease patients.
Olink Proteomics will focus on developing protein biomarker discovery products while Olink Bioscience will work on other technologies arising from its IP portfolio.
The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.
Under the partnership, the University of Miami will provide samples and Berg will analyze them using its Interrogative Biology platform.
The certification covers the development, production, and distribution of in vitro diagnostics for autoimmune disease.
The company's platform mines multiple omics datasets to provide a complete picture of the genes and pathways affected in disease, drug response, more.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.